FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113231429> ?p ?o ?g. }

• W2113231429 endingPage "1023" @default.
• W2113231429 startingPage "1004" @default.
• W2113231429 abstract "Genetic lesions such as BCR-ABL1, E2A-PBX1, and MLL rearrangements (MLLr) are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Leukemia oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype. We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets. We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial (ECOG E2993) and normal control B cells. In BCR-ABL1-positive B-ALLs, aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of IL2RA(CD25). The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of BCR-ABL1 status, suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs. In E2A-PBX1-positive B-ALLs, aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A-PBX1 chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), suggesting that E2A-PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype. MLLr B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6. Notably, BCL6 blockade or loss of function suppressed proliferation and survival of MLLr leukemia cells, suggesting BCL6-targeted therapy as a new therapeutic strategy for MLLr B-ALLs.We conducted the first integrative epigenomic study in adult B-ALLs, as a correlative study to the ECOG E2993 phase III clinical trial. This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation. We identify a novel clinically actionable biomarker in B-ALLs: IL2RA (CD25), which is linked with BCR-ABL1 and an inflammatory signaling network associated with chemotherapy resistance. We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr." @default.
• W2113231429 created "2016-06-24" @default.
• W2113231429 creator A5001124933 @default.
• W2113231429 creator A5003947352 @default.
• W2113231429 creator A5007755251 @default.
• W2113231429 creator A5008264908 @default.
• W2113231429 creator A5014838335 @default.
• W2113231429 creator A5019229900 @default.
• W2113231429 creator A5019770989 @default.
• W2113231429 creator A5020303646 @default.
• W2113231429 creator A5029896152 @default.
• W2113231429 creator A5031756069 @default.
• W2113231429 creator A5034755041 @default.
• W2113231429 creator A5042915360 @default.
• W2113231429 creator A5043014123 @default.
• W2113231429 creator A5050087793 @default.
• W2113231429 creator A5052967210 @default.
• W2113231429 creator A5053376451 @default.
• W2113231429 creator A5053562871 @default.
• W2113231429 creator A5054173720 @default.
• W2113231429 creator A5061170779 @default.
• W2113231429 creator A5061702711 @default.
• W2113231429 creator A5061717752 @default.
• W2113231429 creator A5068847117 @default.
• W2113231429 creator A5069145942 @default.
• W2113231429 creator A5074727195 @default.
• W2113231429 creator A5079511754 @default.
• W2113231429 creator A5085360755 @default.
• W2113231429 creator A5087032705 @default.
• W2113231429 date "2012-11-01" @default.
• W2113231429 modified "2023-10-11" @default.
• W2113231429 title "Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia" @default.
• W2113231429 cites W1965262464 @default.
• W2113231429 cites W1966942042 @default.
• W2113231429 cites W1967358345 @default.
• W2113231429 cites W1968677867 @default.
• W2113231429 cites W1971273349 @default.
• W2113231429 cites W1976672367 @default.
• W2113231429 cites W1977729188 @default.
• W2113231429 cites W1981709629 @default.
• W2113231429 cites W1983641075 @default.
• W2113231429 cites W1992048312 @default.
• W2113231429 cites W1993536389 @default.
• W2113231429 cites W2002213310 @default.
• W2113231429 cites W2002525399 @default.
• W2113231429 cites W2004067791 @default.
• W2113231429 cites W2006537045 @default.
• W2113231429 cites W2006885289 @default.
• W2113231429 cites W2008020601 @default.
• W2113231429 cites W2008420899 @default.
• W2113231429 cites W2012860082 @default.
• W2113231429 cites W2016833582 @default.
• W2113231429 cites W2017580443 @default.
• W2113231429 cites W2018796139 @default.
• W2113231429 cites W2024352108 @default.
• W2113231429 cites W2026123032 @default.
• W2113231429 cites W2027364921 @default.
• W2113231429 cites W2028286264 @default.
• W2113231429 cites W2032692272 @default.
• W2113231429 cites W2044365745 @default.
• W2113231429 cites W2053421436 @default.
• W2113231429 cites W2053856108 @default.
• W2113231429 cites W2063738914 @default.
• W2113231429 cites W2067656626 @default.
• W2113231429 cites W2069918359 @default.
• W2113231429 cites W2073652391 @default.
• W2113231429 cites W2077654571 @default.
• W2113231429 cites W2078972833 @default.
• W2113231429 cites W2082364696 @default.
• W2113231429 cites W2082592723 @default.
• W2113231429 cites W2091151146 @default.
• W2113231429 cites W2091213817 @default.
• W2113231429 cites W2091884937 @default.
• W2113231429 cites W2098362718 @default.
• W2113231429 cites W2098582295 @default.
• W2113231429 cites W2101500536 @default.
• W2113231429 cites W2102193258 @default.
• W2113231429 cites W2102560467 @default.
• W2113231429 cites W2105066639 @default.
• W2113231429 cites W2112075818 @default.
• W2113231429 cites W2112448007 @default.
• W2113231429 cites W2113752195 @default.
• W2113231429 cites W2114358266 @default.
• W2113231429 cites W2114629186 @default.
• W2113231429 cites W2115023583 @default.
• W2113231429 cites W2116909043 @default.
• W2113231429 cites W2124472585 @default.
• W2113231429 cites W2126580353 @default.
• W2113231429 cites W2128919238 @default.
• W2113231429 cites W2131072337 @default.
• W2113231429 cites W2135667448 @default.
• W2113231429 cites W2138218344 @default.
• W2113231429 cites W2139954541 @default.
• W2113231429 cites W2140946267 @default.
• W2113231429 cites W2141410747 @default.
• W2113231429 cites W2147545245 @default.
• W2113231429 cites W2148654292 @default.
• W2113231429 cites W2149052195 @default.

• next